By Annalee Armstrong,Conor Hale,Kevin Dunleavy,Kyle LaHucik
Join us for a rolling look at the top life science news coming out of this year's virtual J.P. Morgan Healthcare Conference.
read more
By Rebecca Torrence
Following a mass exodus of leadership that caused its shares to drop 36% in a week, virtual behavioral health company Talkspace now faces a securities fraud class action lawsuit. The suit alleges the company failed to disclose certain growth headwinds before it went public last June.
read more
By Conor Hale
The next phase will add on heart failure and systemic lupus erythematosus alongside the companies’ ongoing projects in chronic kidney disease and idiopathic pulmonary fibrosis.
read more
By Eric Sagonowsky
When Novartis scooped up The Medicines Company and its promising cholesterol drug inclisiran back in late 2019, the company jumped into a field where some of its pharma rivals had struggled to meet expectations over the years. Now, with approvals on both sides of the Atlantic, Novartis is busy rewriting the drug launch playbook in cardiovascular disease.
read more
By Kyle LaHucik
The FDA has thrown Denali Therapeutics' Alzheimer's med into murky waters with a clinical hold before the drug even enters human trials. The move also impacts Takeda, which just last month moved forward on the pair's 2018 deal by opting to co-develop the drug.
read more
By Fraiser Kansteiner
After a false start in Europe, bluebird bio is determined to give its trio of gene therapies a better shot in the U.S. Bluebird is readying the commercial nest ahead of a May decision on its beta thalassemia gene therapy beti-cel, also known as Zynteglo.
read more
By Nick Paul Taylor
Sarepta Therapeutics is walking away from a partnered gene therapy just months before the readout of a pivotal clinical trial. The biotech stuck with Lysogene through a tough 2020 that featured the death of a child who received their partnered gene therapy but has now decided to exit the deal.
read more
By Dave Muoio
Since Thanksgiving, more than 800 military and other federal emergency personnel have been deployed to support hospitals bending under COVID-19 pressure.
read more
By Andrea Park
On average, using a team of Stanford Medicine researchers' new ultra-rapid technique, the entire sequencing and diagnosis process took just eight hours.
read more
By Angus Liu
Scientists at La Jolla Institute for Immunology have discovered that macrophages in arteries could "smell" its surroundings to trigger inflammation in atherosclerosis. Blocking a key protein receptor involved in the process could be a promising target for treating cardiovascular disease, they said.
read more
By Conor Hale
The collaboration includes an upfront $13 million payment to kick off the company’s R&D projects plus an equity investment in Insilico of an undisclosed amount.
read more
By Robert King
Payer groups applauded CMS' proposal to onlycover the controversial Alzheimer's drug Aduhelm for patients in clinical trials.
read more
By Andrea Park
After spending the past few years laying the groundwork for a full-scale launch of its KidneyIntelX technology, Renalytix is predicting that “2022 is going to be a heavy year of milestones,” according to CEO James McCullough.
read more
